Member Info for Basser1

We have all seen the day after day buying with the share price not moving upward. About time Aim did its job of regulatory monitoring. Destroying company valuations is not helping UK growth as has been reported in the press.

Agree Aber -and it would be in line with the Sareum strategy - “Our approach is to discover and develop programmes to late preclinical and early clinical”.

Re SRA737 - longer term Holders can recall a statement by Stephen Dilley, the CEO of Sierra Oncology regarding SRA737 - that it was very likely to be more lucrative than Momelotinib. I would not don’t think he was someone who was prone to exaggeration.

Just out of interest, there was a 30p buy at 15.38 this afternoon which is not showing. Might be a big delayed buy?

MMS taking pis - the unknown trades are buys surely ( they would have been shown as sells). About time share price is let off the leash!

Hi fearg

Yes. Working on the assumption that the Board would be sharing very good findings with as many Parma's as possible.

If the quality and and evidence of multiple applications are as good as we hope then there will be a bidding process which will in my opinion will be well above £3. Don’t even think the Board would put a low offer to the shareholders.

We have all got our views on how the Sareum saga will end. I am going with the buyout at an early stage as the alternative ie licensing does not seem to fit with having 1801 and 1802. As Snoop stated yesterday, it does not make sense to license 1801 and leave 1802 to a competitor. The price will ultimately be determined by the amount of multiple indications - and licensing would have to cover all of these aspects.

Confer meaning - grant to, award to, bestow on (significant advantages)

Re - significant advantages -should attract pharmas to be queuing up to ask how and why.

Rose tinted glasses perhaps, but to me, the length of time hopefully suggests a number of indications,

Fingers crossed

If the CEO is traditionally a visible part of your start up and you haven’t seen them around much, there may be an acquisition looming. Let’s hope so soon! lol.

PC- nice post. But I still don’t get why a next generation kinase inhibitor with potential multi applications should not be the going market rate ( say around a billion) just because a share price has been lowered by dilution. Can you explain please?

It’s the market value and potential of the TYK2 inhibitors that matters, not the share price surely?. Especially if there are multiple applications.

I thought that MMs have to make a market. Not when it suits them?

No trading for an hour. Can anyone buy?

Whatever the final outcome, do we really think that a pharma is going to pick up SDC1801/1802 on the cheap (£5 has been mentioned) - given the low toxicity results, once a day tablet form and best in class potential covering autoimmune and Cancer? Many pharmas patents are running out. Any first offer will only be the start of a very competitive bidding process which should significantly raise the offer. Let’s be clear - no pharma is going to let a competitor get away with a cheap buy with the top quality inhibitors that Sareum has. Market Capital does not determine the outcome of an offer it is the value of the inhibitors that with multiple application is likely to start in the billions. Just sit tight.

Well said warthog. Let’s try and get the 95% holders to all buy at once. That would fk this lot up.

Here to me is yet another example where the regulatory bodies of LSE/Aim are seemingly doing nothing to increase valuations of hi tec British Biotecs. Sareum is my opinion is very likely to be world leading with SDC 1801 and SDC1802 but watch all the barriers and short termism put in its way to prevent its progress. Are you listening LSE? I doubt not.

Would cover 1801 AND 1802. Happy days!